← Eichor
Study identifier: NCT05784311 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)

Condition: Pancreatic Cancer  ·  Sponsor: Leiden University Medical Center

PhasePhase 4
Planned participants344
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. The main objectives it aims to answer are: * To evaluate the effect of pre-emptive antibiotic prophylaxis on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile * To evaluate the effect of pre-emptive antibiotic prophylaxis on other postoperative outcomes (e.g. OSIs, superficial SSIs, POPF, PPH, major morbidity, ICU admission, readmission, length of hospital stay, and mortality). * To evaluate concordance between perioperatively obtained bile cultures and postoperative cultures from infectious sites, and to evaluate antibiotic sensitivity patterns of the cultured microorganisms. Participants will be randomized with a 1:1 allocation before surgery into the intervention or control group: * Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily. * Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Daphne HM Droogh, MD  ·  071 5261334  ·  d.h.m.droogh@lumc.nl

Always discuss trial participation with your own doctor first.

Locations (11)

Leiden University Medical CenterLeiden, South Holland, NetherlandsRecruiting
Jeroen Bosch Ziekenhuis's-Hertogenbosch, NetherlandsNot Yet Recruiting
Amsterdam University Medical CenterAmsterdam, NetherlandsRecruiting
Amphia ZiekenhuisBreda, NetherlandsRecruiting
Catharina ZiekenhuisEindhoven, NetherlandsRecruiting
Medisch Spectrum TwenteEnschede, NetherlandsRecruiting
Groningen University Medical CenterGroningen, NetherlandsRecruiting
Maastricht University Medical CenterMaastricht, NetherlandsRecruiting
Radboud University Medical CenterNijmegen, NetherlandsRecruiting
Erasmus MC Cancer InstituteRotterdam, NetherlandsRecruiting
Regional Academic Cancer Center UtrechtUtrecht, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05784311